We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives
- Why Is It Important?
- Reproductive and developmental toxicology
- Why is this field important?
- Birth defects occur in about 6% of all births
- Thalidomide tragedy
- Methyl mercury tragedy
- Guidance for testing
- The outgrowth of tragedies
- Intentional and unintentional exposure
- Underlying principles (1)
- Underlying principles (2)
- Example (1)
- Example (2)
- Example (3)
- Susceptibility of fetal organs
- Death or failure to thrive
- Malformation
- Growth retardation
- Functional deficits
- Basic guidelines
- Basic guidelines for drugs
- Chemicals (OECD or EPA-specific)
- Chemicals (OECD specific)
- Foods and food additives
- Guidance for intentional exposure (drugs) (1)
- Developmental and reproductive toxicology - life stages
- ICH guidelines S5R - choice of studies
- Vaccine study design
- NHP enhanced PPND study design (ePPND) combine EFD + PPND into one study
- Male reproduction in chronic toxicity study (≥ 3M duration, sexually mature NHPs, non-mating)
- Female reproduction in chronic toxicity study (≥ 3M duration, sexually mature NHPs, non-mating)
- Unintentional Exposure
- Guidance for unintentional exposure
- Multigeneration study
- OECD 443 (1)
- OECD 443 (2)
- Endpoints
- Paternal/Maternal endpoints
- Reproductive endpoints
- Developmental endpoints
- Functional testing
- Outcomes (1)
- Hazard assessment
- Outcomes (2)
- Conclusions
Topics Covered
- Importance of reproductive and developmental toxicology
- Reproductive and developmental toxicology: milestones
- Basic guideline studies
- Selection of species
- Endpoints of paternal, maternal, reproductive, and developmental toxicity
- Outcomes used to determine the hazard
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Hoberman, A. (2021, July 28). Reproductive and developmental toxicology [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/NQJN7536.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Reproduction & Development
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to the module on reproductive and developmental toxicology.
I'm Alan Hoberman, I'm the Executive Director for global reproductive, developmental,
and juvenile toxicology at Charles River Laboratories, Preclinical Services.
0:13
The objectives of today's talk will be:
to describe the importance of reproductive and developmental toxicity testing;
to describe the guidance for testing of reproductive and developmental toxicants;
to provide an overview of reproductive and developmental toxicity endpoints;
and finally to describe the outcomes of this type of testing.
0:32
Reproductive and developmental toxicology, why is it important?
0:37
Reproductive and developmental toxicology is a specialty area of toxicology.
It looks at the potential adverse effects of a test material, drug, medical device, or chemical.
It looks at what the effects of these are on male and female fertility,
the ability to produce offspring,
and the growth and maturation of future generations.
0:58
Why is this field important?
Today, we have smaller family sizes, and we want to
plan and have families when we want them.
There's an even greater need to be able to produce healthy offspring when we want them.
1:11
Birth defects occur in about six percent of all births in humans,
and also there's going to be a background rate in any species that we look at.
The causes of these birth defects hasn't changed much over the years,
I am presenting some data here developed in 1988 by Brent and Holmes, published in Teratology,
which is the journal for the society that studies birth defects
(now called Birth Defects Research and Prevention Society),
you can see from this slide that genetic diseases account
for between 10 and 25 percent of all birth defects.
Unknown causes is the largest group, we still don't know what causes them,
65 to 75 percent of all birth defects are unknown,
although as we identify more genetic diseases that number may get a little lower.
Only about 10 percent of all birth defects appear to have an environmental cause.
Some of those could be from maternal disease states such as diabetes,
we know diabetic women have a higher rate of birth defects in their offspring.
Metabolic deficiency, or if you had too much vitamin A or too little vitamin A in your diet,
you could cause a birth defect, that's classically known.
Mechanical problems in utero, the umbilical cord can get constricted around a limb and
cause a deformed limb, and other accidents can occur in utero.
Then there are drugs, chemicals, and radiation,
which appear to cause less than one percent of all birth defects.
However, when a drug or a chemical or radiation does cause a birth defect
it can be very serious, and it is also very preventable.